Predicting hypoxia in cystic fibrosis patients during exposure to high altitudes  by Kamin, Wolfgang et al.
www.elsevier.com/locate/jcfJournal of Cystic FibrosisPredicting hypoxia in cystic fibrosis patients during exposure to
high altitudesB
Wolfgang Kamin a,*, Birthe Fleck b, Dirk-Mathias Rose b, Oliver Thews c, Wolfgang Thielen a
a Children’s Hospital, Mainz University, 55101 Mainz, Germany
b Institute of Occupational, Social and Environmental Medicine, Mainz University, Germany
c Institute of Physiology and Pathophysiology, Mainz University, Germany
Received 9 September 2005; received in revised form 15 February 2006; accepted 9 March 2006
Available online 19 May 2006Abstract
Background: For patients with cystic fibrosis (CF)-related partial respiratory insufficiency and reduced arterial oxygen tension at ground
level, the mild hypobaric environment on commercial jet aircraft poses the risk of severe hypoxemia. Thus, physicians should be able to
estimate the extent of in-flight hypoxia.
Objectives: To derive tools for estimating the expected drop in arterial oxygen partial pressure (paO2) and oxygen saturation (saO2) in young
adult CF patients with mild to moderate airway obstruction during exposure to the hypobaric conditions aboard commercial aircraft and to
test the predictive power of a hypobaric chamber simulation.
Methods: Blood gases of 12 CF patients were measured at ground level, at two altitudes in a hypobaric chamber (2000 and 3000 m) and
during two 3.5-h flights at cabin altitudes of 1855 m and 1700 m. The altitude dependence of paO2 and saO2 in the chamber and during the
flights was calculated and results were used to derive estimation equations for in-flight values.
Results: In the chamber, saO2 decreased by 0.33% per 100 m vertical ascent, and this rate increased significantly at altitudes >2000 m.
Predicted saO2 differed from in-flight value by <5%, and agreement between in-flight saO2 decrease rate and chamber data was good. paO2
decreased at a rate of 0.99 mm Hg/100 m in the chamber and by 1.33 mm Hg/100 m during flights. None of the subjects showed any clinical
symptoms during the flights and the chamber simulation.
Conclusion: During our worst-case scenario, i.e. the hypobaric chamber simulation at 3000 m, 90% of patients tolerated paO2 values below
the commonly recommended threshold of 50 mm Hg, probably due to adaptation to chronic hypoxemia and lung function impairment. We
propose the following equations for an estimation of the expected extent of in-flight hypoxemia in CF patients with mild to moderate airway
obstruction and a flight duration of up to 3.5 h:
– paO2 [Alt] =paO2 [ground]1.33Alt [mm Hg], and
– saO2 [Alt] =saO2 [ground]0.33Alt [%], with Alt=altitude in 100 m.In addition to the overall clinical situation of a patient, these equations will serve as a practical supportive tool for the assessment of the
fitness to fly in the primary care setting.
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For patients with cystic fibrosis (CF)-related respiratory
insufficiency and reduced arterial oxygen tension at
ground level, the decrease in arterial oxygen partial
pressure (paO2) in the mild hypobaric environment on
commercial jet aircraft poses the risk of severe hypox-
emia. The International Civil Aviation Organisation
(ICAO), the Aerospace Medical Association as well as
the British and American Thoracic Society guidelines
recommend administration of supplemental oxygen if
paO2 drops below the critical threshold of between 50
mm Hg (6.7 kPa) and 55 mm Hg (7.3 kPa) at cruising
altitude. Previous research has attempted to assess the
fitness to fly in diverse patient populations by using pre-
flight blood gas values and lung function indices as
predictors for in-flight hypoxia [1–9]. A paO2 of 70
mm Hg prior to the flight is regarded as the most reliable
predictor for critical in-flight paO2 [1,4,11–14]. Alterna-
tively, hypoxia-altitude simulations tests (HAST) in a
hypobaric chamber [1–3] or by inhalation of hypoxic gas
mixtures [4–7,10] have been performed in order to
predict potentially life-threatening conditions during flight
or similar exposure to hypoxic conditions at high altitude
[10].
The objective of the present study was to compare
the extent of altitude-induced hypoxia in 12 young adult
CF patients during a hypobaric chamber simulation test
and during two flights between Frankfurt/Main, Ger-
many and Gran Canaria, Canary Islands, Spain. The
study was designed to test the accuracy of hypoxic
response estimation for this particular risk group, by
quantifying the changes in arterial paO2 and saO2 in
both hypobaric settings and derive estimation models
enabling the clinician to assess CF patients’ fitness to
fly.Table 1
Patient characteristics and results of spirometric tests (lung function) of all subjec
Patient no./sex Age [years] FVC [l] FVC %
predicted
normal
1/f 31 2.85 91.84
2/m 34 3.69 70.49
3/f 32 1.63 51.41
4/m 19 2.75 50.92
5/m 26 3.68 76.60
6/f 31 1.37 45.78
7/m 34 3.95 82.49
8/f 35 2.81 90.80
9/m 32 3.93 76.99
10/m 25 1.85 40.33
11/m 26 3.88 84.52
12/m 31 2.92 57.00
Mean 29.7 3.13 68.26
S.E.M. 1.4 0.28 5.28
Median 31 3.11 73.542. Materials and methods
2.1. Study population
The study population consisted of 12 young adult
ambulatory CF patients (8 male, 4 female) aged 19 to 35
years, undergoing treatment at the CF Centre of University
Children’s Hospital Mainz, Germany. Baseline lung function
characteristics (Table 1) indicate that the study population
included patients with mild to severe respiratory insufficien-
cy (FEV1 % of predicted normal: 55.31T6.65 [24.34;
92.95]%; FVC % of predicted normal: 68.26T5.28 [40.33;
91.84]%; FEV1/FVC: 67.86T5.22 [40.3; 90.9]%; all values
reported as meanTS.E.M. [min.; max.]), with the majority of
the patients (8 of 12) having baseline FEV1 values <70%
predicted normal. None of the included patients had severe
concomitant pulmonary or other diseases (such as pulmonary
exacerbation, pneumothorax, cor pulmonale). At baseline
(i.e. ground level of 120 m a.s.l.), 3 patients had a paO2 value
70%, 2 patients had an saO2 value 92%.
Eleven of the patients participated in a complete 3-week
physiotherapy program (2 units of exercise every day) in
Gran Canaria. On the outward flight from Frankfurt to Gran
Canaria (flight 1, duration approx. 3.5 h), all 12 patients
were examined. Due to flight rescheduling, only 8 patients
were available on the return flight to Frankfurt (flight 2,
duration approx. 3.5 h).
2.2. Methods
Ground-level partial pressures of blood gases (paO2,
pCO2), oxygen saturation (saO2) and lung function indices
(FEV1, FVC, PEF) were measured at Mainz University
Children’s Hospital (120 m a.s.l.; pb=747 mm Hg; pIO2=
152 mm Hg). Subsequently, the same parameters were
measured during a hypobaric chamber altitude simulationts at ground level in Mainz; f= female, m=male
FEV1 [l] FEV1 %
predicted
normal
FEV1/FVC [%] PEF %
predicted
normal
2.8 92.95 90.9 81.32
2.1 47.84 70.2 76.81
1.2 39.61 51.0 54.96
1.8 37.17 50.8 46.51
3.6 76.65 76.2 82.95
0.7 24.34 45.3 36.73
2.7 63.62 82.1 77.08
2.4 82.53 89.9 130.46
2.1 49.88 76.7 45.48
1.4 34.78 40.3 63.64
3.3 80.59 84.1 76.98
1.5 33.71 56.8 52.72
2.13 55.31 67.86 68.80
0.25 6.65 5.22 7.23
2.08 48.86 73.20 70.23
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Fig. 1. Altitude dependence of arterial oxygen partial pressure (paO2).
Given are values of all subjects at ground level (120 m a.s.l.; n =12), in the
hypobaric chamber (2000 and 3000 m; n =9 and n =8, respectively) and
during the two flights (1700 and 1855 m; n =8 and n =10, respectively).
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Fig. 2. Altitude dependence of oxygen saturation (saO2). Given are values
of all subjects at ground level (120 m a.s.l.; n =10), in the hypobaric
chamber (2000 and 3000 m; n =10) and during the two flights (1700 and
1855 m; n =8 and n =10, respectively).
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Mainz University. Blood gases, oxygen saturation and lung
function were measured at simulated altitudes of 2000 m
(=6561 ft; pb=580 mm Hg; pIO2=117 mm Hg) and 3000 m
(=9842 ft; pb=513 mm Hg; pIO2=102 mm Hg). To simulate
the cabin depressurisation rate aboard commercial aircraft,
the ascent and descent speed was set to 200–300 m/min,
with 5- to 10-min stops at the specified altitudes for steady-
state data acquisition. The entire chamber simulation lasted
40–50 min.
Immediately before flight 1, lung function and oxi-
metric measurements were repeated at Frankfurt/Main
Airport (172 m a.s.l.). In-flight hypoxemia was assessed
by one blood gas analysis, two spirometric tests and one
oximetric measurement during flight 1 (cabin altitude=
1855 m=6086 ft) and flight 2 (cabin altitude=1700 m=
5577 ft). To ensure steady state, saO2 measurements were
performed after 45 min of calm flight at cruising altitude.
Data acquisition was completed with spirometric and
oximetric measurements at Gran Canaria airport (23 m
a.s.l.) and a control measurement 1 week after return at
Mainz University’s Children’s Hospital. Because the four
measurements performed at ground level differed only
slightly we only report data from the first measurements
in Mainz and use only this data for the calculations of the
decrease in paO2 and saO2.
Blood gas analysis was performed with the portable self-
calibrating pressure-adjusted blood gas analyzer Opti 1
(AVL, Schaffhausen, Switzerland) which also provided the
cabin altitude values. Lung function was assessed with the
Vitalograph 2120 spirometer (Vitalograph Ltd., Bucking-
ham, UK), checked for accuracy and linearity with a 1-
l precision syringe prior to the chamber experiments. For
transcutaneous oxygen saturation measurements, Oximeter
9500 (Nonin Medical, Plymouth, USA) was used. All
devices were calibrated before each measurement. All
participating patients gave their written informed consent,
and the study was approved by Mainz University’s ethics
committee.2.3. Analysis
The altitude dependence of paO2 and saO2 in the
hypobaric chamber and during the two flights was
determined by using the individual measurements at each
altitude and by calculating the decreases (absolute, i.e.
DpaO2 and DsaO2; altitude-relative, i.e. DpaO2/DAlt and
DsaO2/DAlt) for both variables at cruising altitudes. Flight
and chamber data (absolute values, absolute decreases,
altitude-relative decreases) were compared with nonpara-
metric tests for paired samples (Wilcoxon matched pair
signed rank test) at a significance level of a =0.05. All
statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, version 9.0).3. Results
Figs. 1 and 2 show the absolute values of arterial oxygen
partial pressure (paO2) and oxygen saturation (saO2),
respectively, of all subjects at the simulated altitudes in
the chamber and during the 3.5-h flights. At all altitudes,
measurements showed a high inter-individual variability. At
3000 m, only one patient maintained a paO2 value >50 mm
Hg, while the other subjects tolerated paO2 values between
43 and 49 mm Hg without discomfort or dyspnea. Two
patients, although asymptomatic before the chamber simu-
lation, developed mild ear barotraumas, but recovered after
administration of decongestant nose spray. Two female
patients discontinued due to claustrophobia. Furthermore
there was one subject with a slightly higher paO2 value at
2000 m (hypobaric chamber) than at ground level (73 vs.
70 mm Hg).
Similarly we found slightly higher saO2 values in two
patients during return flight than at ground level (93.5% vs.
93%).
Table 2 shows paO2 and saO2 reported as median with
minimum and maximum values at ground level and the
4 different altitudes. Measurements in the hypobaric chamber
Table 2
Values of oxygen partial pressure (paO2), oxygen saturation (saO2) and carbon dioxide partial pressure ( pCO2) at ground level (120 m a.s.l.), in the hypobaric
chamber (2000 and 3000 m) and during the two flights (1700 and 1855 m), reported as median (minimum; maximum)
Ground Chamber Flight 1 Flight 2
120 m a.s.l. 2000 m a.s.l. 3000 m a.s.l. 1855 m a.s.l. 1700 m a.s.l.
paO2 [mm Hg] 79 (52; 90) 60 (47; 73) 45.5 (43; 52) 55.5 (45; 64) 60 (44; 64)
saO2 [%] 95 (88; 97) 89 (84; 94) 86 (80; 89) 90.5 (77.5; 94) 94.5 (85; 95.5)
pCO2 [mm Hg] 42 (38; 46) 37 (32; 41) 34 (29; 37) 35 (32; 41) 37 (34; 41)
W. Kamin et al. / Journal of Cystic Fibrosis 5 (2006) 223–228226showed median decreases from 79 mm Hg at ground level to
60 mm Hg (2000 m) and 45.5 mm Hg (3000 m) in paO2 and
from 95% to 89% (2000 m) and 86% (3000 m) in saO2.
In-flight median paO2 decreased from a ground-level
value of 79 mm Hg to 55.5 mm Hg during flight 1 and to 60
mm Hg during flight 2. Two patients with paO2 <60 mm Hg
at ground level sustained in-flight values of 46 and 45 mm
Hg without experiencing discomfort or shortness of breath.
In-flight median saO2 decreased from a ground-level value
of 95% to 90.5% during flight 1 and to 94.5% during flight
2. During flight 1, one patient had an saO2 value of only
77.5%, but also developed no clinical symptoms.
3.1. Comparison of hypobaric chamber and in-flight data
As shown in Table 3, the median decreases of paO2 (in
percent of ground-level value) were in good agreement for
the flights and the hypobaric chamber at 2000 m, with
slightly lower decreases during flight 2 (24.05% vs.
29.75%). In contrast, the median decreases of saO2 in
the chamber (2000 m) were only in accordance with flight
1 data. During flight 2 the median drop of saO2 was only
0.53% (as compared to 4.74% during flight 1), and two
patients showed even slightly higher values than at ground
level (see above).
The per-unit paO2 decrease rates during both flights
(1.326 mm Hg/100 m [flight 1] and 1.329 mm Hg/100 m
[flight 2]) were significantly higher than those observed in
the chamber (1.146–1.170 mm Hg/100 m). In contrast, the
per-unit saO2 decrease rate for flight 1 (0.357%/100 m) was
in good agreement with that derived from the chamber data
(0.33%/100 m).
Both during the flights and in the chamber, a decrease in
mean (TS.E.M.) pCO2 was noted, from a ground-level
value of 41.63T0.88 mm Hg to between 37.13T0.79 mmTable 3
Comparative summary of decreases in arterial oxygen partial pressure (paO2) and
two flights
Chamber
2000 m a.s.l.
DpaO2 Absolute mm Hg 19 (0; 29)
DpaO2 % of ground value 24.05 (0; 38.2)
DsaO2 Absolute % 6 (3; 11)
DsaO2 % of ground value 6.32 (3.1; 11.6)
Data are reported as median (minimum; maximum). Absolute and perce
DX =(X[ground]X[Alt])/X[ground]100).Hg (1700 m, flight 2) and 33.63T1.00 mm Hg (chamber,
3000 m).
No relevant correlations (correlation coefficients mostly
<0.1) were found between the decreases in paO2 and saO2
and ground-level FEV1/FVC. In contrast, in-flight paO2
values were strongly correlated with ground-level FEV1
values, with correlation coefficients ranging from 0.92
(flight 1) to 0.37 (chamber, 3000 m).4. Discussion
The objective of this study was to derive an estimating
model enabling the general practitioner to calculate the
expected extent of hypoxia in CF patients with mild to
moderate respiratory insufficiency during exposure to
hypobaric environments and to test the predictive power
of a hypobaric chamber simulation.
The present measurements corroborate the linear de-
crease in paO2 up to altitudes of 2000 m [4,8,17,18]. Due to
the observed discrepancy in paO2 between the hypobaric
chamber and in-flight data, an equation cannot be derived
from the chamber data. This discrepancy is probably due to
(a) better steady-state conditions aboard the aircrafts due to
longer adaptation (45 min vs. 5–10 min in the chamber),
(b) higher ascent speed during the chamber simulation than
during the flights, (c) flight-related stress. The in-flight
paO2 decrease rates (1.326 mm Hg/100 m [flight 1] and
1.329 mm Hg/100 m [flight 2]) will serve as more reliable
predictors for paO2 at the expected cabin altitude and for
flights of a duration of up to 3.5 h. These in-flight values
correspond well with that reported by Lien and Turner (4 mm
Hg/1000 ft=1.314 mm Hg/100 m) [8], but are higher than
that found by Fischer et al. (1.00 mm Hg/100 m, resulting
from a median drop of 2.8 kPa [21.2 mm Hg] and an altitudeoxygen saturation (saO2) in the hypobaric chamber (2000 m) and during the
Flight 1 Flight 2
1855 m a.s.l. 1700 m a.s.l.
23.5 (6; 30) 19 (11; 33)
29.75 (11.5; 38) 24.05 (15.7; 36.7)
4.5 (3; 10.5) 0.5 (0; 3)
4.74 (3.2; 11.9) 0.53 (0; 3.4)
nt decreases were calculated as follows: DX =X [ground]X [Alt] and
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cogwheel train/cable car at considerably lower ascent
speeds than in the present study [10]. We therefore
propose the following estimation equation (based on the
per-unit decreases of paO2 during the flights) for young
adult CF patients with mild to moderate respiratory
insufficiency and for flights of up to 3.5 h in duration:
paO2 Alt½  ¼ paO2 ground½   1:33
 Alt mm Hg½  Alt ¼ Altitude in 100 mð Þ:
Good agreement was found for saO2 between chamber
and flight 1 data, and the decrease in saO2 during exposure to
cabin altitude of 1855 m corresponds well with that reported
by Oades et al. who studied hypoxia in children with CF
during HAST and exposure to comparable altitudes [16];
however, the per-unit decrease was again higher than that
found by Fischer et al. (0.24%/100 m, resulting from a
median drop of 5% and an altitude difference of 2120m) [10].
We therefore propose the following equation to estimate the
expected in-flight saO2 at typical cabin altitudes of up to 2000
m and for flights of up to 3.5 h in duration, based on the per-
unit decrease of saO2 during the hypobaric chamber
simulation:
saO2 Alt½  ¼ saO2 ground½   0:33 Alt %½ 
 Alt ¼ Altitude in 100 mð Þ:
The median decrease in paO2 during flight 2 (cabin
altitude 1700 m) (Table 3) was lower than during flight 1
(cabin altitude 1855 m). Even more pronounced, saO2 values
dropped only slightly during the return flight. Assuming no
effect of altitude difference (1700 vs. 1855 m), we suppose
that this reduced risk for in-flight hypoxia is due to climate
change and 3 weeks of intensified physiotherapy (exercises
twice a day) on Gran Canaria improving CF patients’ fitness
to fly. Lung function indices (FEV1, FVC) corresponded
well, with between 10% and 20% higher values during the
return flight. Considering this improvement, we generally
recommend routine physiotherapy for CF patients, especially
before intended travel to high altitudes [15].
For patients with mild to moderate respiratory insuffi-
ciency, the extent of hypoxemia at 3000 m cabin altitude–
close to the cabin altitude allowed by US Federal Aviation
Administration regulations–represents a worst-case scenar-
io. During the present hypobaric chamber simulation at that
altitude, 90% of patients sustained oxygen partial pressures
below the commonly recommended threshold value of 50
mm Hg. The fact that none of these patients had any
discomfort or clinical symptoms corroborates that young
adult CF patients with only mild to moderate respiratory
insufficiency [10] or patients with COPD [14] may tolerate
paO2 values below the commonly recommended threshold
of 50 mm Hg, as these patients are likely to be adapted to
chronic lung function impairment and hypoxia.The considerable range of lung function impairment and
oxygenation of the included patients was reflected in the
high inter-individual variability of lung function and
oxygenation at all assessed altitudes. The fact that in-
flight paO2 value was strongly correlated with the ground-
level FEV1 value further supports the claim that FEV1
may be another important predictor of paO2 at altitude and
should be retained in the fitness-to-fly guidelines
[1,2,5,7,10], so that artificial oxygenation can be planned
for patients with severe airway obstruction or such patients
can be discouraged from air travel altogether. However, we
would argue that lung function is after all an indirect,
secondary assessment in the context of hypoxemia, and we
therefore refrain from including FEV1 in our estimation
equations and from proposing an alternative FEV1
threshold value.
As seen in the present and previous studies, patients
with respiratory obstruction can partially compensate
hypoxemia through compensatory hyperventilation (as
reflected in the drop in arterial pCO2) [7,10,16], so that
the abovementioned equations may be assumed to under-
estimate the decrease in paO2 that would be expected
during normal tidal breathing. However, the fact that these
equations factor in the expected presence of hyperventila-
tion is a more realistic reflection of the extent of
hypoxemia as well as the concomitant situational stress
associated with air travel.
As CF patients in the age-group under consideration,
particularly those with only mild to moderate respiratory
impairment, have the same demands for mobility as their
healthy peers, we consider the estimating tools derived
from the present data as useful in clinical practice. With
cabin altitudes onboard modern commercial aircraft
commonly ranging from 5000 ft (=1524 m) to 7000 ft
(=2134 m) [12], the equations provided will be applicable
to the majority of flights of up to 3.5 h in duration.
Considering these hypobaric conditions during commer-
cial flights, further simplification of these equations is
possible by using the factor 20 for an altitude of 2000 m
a.s.l.:
paO2 Alt½  ¼ paO2 ground½   26:6 mm Hg½ 
and
saO2 Alt½  ¼ saO2 ground½   6:6 %½ :
The cited equations enable the general practitioner to
estimate the individual CF patient’s expected drop in paO2
and saO2, to adjust pre-flight preparatory measures accord-
ingly and to consider the provision of supplemental oxygen
during flight particularly for patients with severe respiratory
impairment. For additional reassurance in the estimation of
expected drop in saO2, the higher saO2 decrease rate in the
2000–3000 m interval (Table 2) can be employed to
perform a worst-case calculation. Furthermore, the hypo-
baric chamber simulation for pre-flight risk assessment has
W. Kamin et al. / Journal of Cystic Fibrosis 5 (2006) 223–228228proved not only reliable for estimating the physiological
response as such, but is also more suitable to mimic the
spatial conditions and psychological atmosphere of the
actual flight situation than the inhalation of hypoxic gas
mixtures (HIT), although the latter may be preferred for
cost-efficiency and practicability [10]. Should a hypobaric
chamber be available, we recommend simulating flight
conditions by a straight ascent at a speed of between 200
and 300 m/min to a single target altitude at or above 2000 m
and a blood gas analysis/oximetry after an adaptation period
of at least 15 min.
As our study sample was comparatively small, the inter-
individual variations in patients’ lung function and adapt-
ability to hypobaric conditions were large and the duration
of the flights comparatively short, the present equations
should be used for an approximation only and should be
applied only to young adults with CF and mild to moderate
respiratory insufficiency and to flights of a duration of up to
3.5 h. Of course, any assessment of fitness to fly in an
individual CF patient should take into account the entire
clinical condition, with particular emphasis on severe
respiratory impairment and potential additional risk factors
from severe concomitant diseases [10]. Extra precautions
should therefore be taken for CF patients with severe
respiratory impairment, and supplemental oxygen should be
available on board. We have aimed to provide a practical
tool to aid the primary care physician in his assessment of
fitness to fly in young adult CF patients with mild to
moderate respiratory insufficiency and adaptation to chronic
hypoxemia. If a patient is assessed to be fit to fly after all,
the psychological benefit for the patient from being able to
enjoy the opportunity of air travel must not be under-
estimated and will contribute positively to the patient’s
quality of life. An additional study would have to be
conducted to expand the present findings to long-distance
flights.Acknowledgments
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